The study also found that taking low-dose aspirin daily increases a patient's risk of bleeding, but the researchers said the protective benefits of aspirin outweigh this side effect. A daily dose of aspirin is considered low if it is between 81 milligrams and 325 milligrams.
"Among patients with stable cardiovascular disease, we found that low-dose aspirin reduced incidence of heart attack, stroke and death," said cardiology fellow Jeffrey Berger, M.D., who presented the results of the study on Wednesday, Nov. 15, at the annual scientific sessions of the American Heart Association, in Chicago.
"We also saw an increased risk of bleeding among patients taking aspirin, but as in the decision-making process involving any therapy, there is always the weighing of benefits and risks," Berger added. "Since a great majority of patients can tolerate aspirin, the benefits appear to outweigh the risks. Aspirin is a drug that has been used for many years. It is well-understood, effective, inexpensive and widely available. In aspirin we have a proven life-saver."
The study was supported by Duke's Division of Cardiology.
Aspirin exerts its protective effect by preventing the clumping together of platelets circulating in the blood, according to the researchers. It is this anticlotting action that also causes unwanted bleeding.
In the Duke study, Berger and colleagues combined the data from six clinical trials that enrolled patients with stable cardiovascular disease or stable angina, or chest pain, and gave them low-dose aspirin. In total, the trials included 9,853 patients.
The researchers found that patients who took low-dose aspirin had a 26 percent reduction in the risk of a nonfatal heart attack, a 25 percent reduction in the risk of stroke and a 13 percent reduction in risk of death, compared with similar heart patients who did not take aspirin. Taken together, Berger said, patients on low-dose aspirin had a 21 percent reduction in risk of experiencing a major cardiovascular event, a measurement that is the combination of the rates of nonfatal heart attack and stroke and of cardiovascular death.
In terms of aspirin's effect in promoting bleeding, the study found that one patient out of 111 who received low-dose aspirin experienced a bleeding episode, Berger said.
Putting the results another way, Berger said, the results suggest that treating 83 patients will prevent one nonfatal heart attack, treating 40 patients will prevent one stroke, treating 30 patients will prevent one major cardiovascular event and treating 71 patients will prevent one death.
"When compared to other medications that have been proven effective in preventing cardiovascular events, aspirin comes off looking very good," Berger said.
For example, 91 patients would need to be treated with ACE inhibitors to prevent one death, compared with 71 patients for aspirin, he said. ACE inhibitors dilate blood vessels, making it easier for the heart to pump blood. Ninety-one patients would need to be treated with the inhibitors to prevent one heart attack, compared with 83 for aspirin, and 167 would need to be treated with the inhibitors to prevent one stroke, compared with 40 patients with aspirin.
"These comparisons show that a cheap and inexpensive medicine like aspirin is just as good, if not better, than other expensive medicines," Berger said.
Still, there is room for improvement in aspirin therapy, he said. In particular, he said, more study is needed to identify what dosage in the low-dose range -- from 81 milligrams to 325 milligrams a day -- will provide the best benefit-to-risk profile.
Richard Merritt | EurekAlert!
Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania
The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.
The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
17.01.2017 | Earth Sciences
17.01.2017 | Materials Sciences
17.01.2017 | Architecture and Construction